Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582332 | 1.00 | ABL1 (0.46) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL8295820 | 0.85 | ABL1 (0.46) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL30279379 | 0.85 | ABL1 (0.46) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL6736660 | 0.84 | GUSB (0.45) | ABL1GAAALDH1A1HSD17B10CA12 | |
| SCHEMBL543638 | 0.84 | ABL1 (0.45) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL31636585 | 0.84 | ABL1 (0.45) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL3347102 | 0.82 | ABL1 (0.44) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL18688327 | 0.82 | ALDH1A1 (0.40) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL11325751 | 0.81 | ABL1 (0.46) | ABL1GAAALDH1A1HSD17B10CFTR | |
| SCHEMBL6137724 | 0.81 | POLB (0.36) | ABL1GAAALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-1515956-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1515956-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Smithkline Beecham (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104209-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885GAA 4568/4885ALDH1A1 3354/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885GAA 4568/4885ALDH1A1 3354/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885GAA 4568/4885ALDH1A1 3354/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | ABL1 534/4885GAA 587/4885ALDH1A1 2996/4885 |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | ABL1 1481/4885GAA 403/4885ALDH1A1 1461/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885GAA 4568/4885ALDH1A1 3354/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | ABL1 1197/4885GAA 380/4885ALDH1A1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.